Skip to content

A Study on How Dark Spots are Reduced When You Use Kumkumadi Oil

Exploring the Physiological Effects of Topical Kumkumadi Taila on Cutaneous Microcirculation and Melanogenesis in Hyperpigmentation: A Dermatoscopic Study - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/03/082810
Enrollment
200
Registered
2025-03-19
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L814- Other melanin hyperpigmentation

Interventions

None listed

Sponsors

Parul Institute of Ayurved
Lead Sponsor
Vasu Healthcare Pvt Ltd
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Skin Type : Fitzpatrick skin types III-VI (to ensure relevance to individuals prone to hyperpigmentation). Hyperpigmentation Diagnosis: Clinically diagnosed with one of the following types of hyperpigmentation: Melasma, Post-inflammatory hyperpigmentation, Solar lentigines (sun spots)

Exclusion criteria

Exclusion criteria: Pregnancy or Lactation: Pregnant or breastfeeding women (due to potential hormonal influences on pigmentation). Active Skin Infections: Presence of active skin infections or inflammatory conditions (e.g., eczema, psoriasis) at the study site (to avoid confounding the assessment of hyperpigmentation).

Design outcomes

Primary

MeasureTime frame
Changes in cutaneous microcirculation parameters (vessel density, morphology) within and around hyperpigmented lesions assessed via dermatoscopy at baseline, 8 weeks, and 12 weeks. Alterations in melanin distribution patterns within hyperpigmented lesions as observed through dermatoscopy at baseline, 8 weeks, and 12 weeks.Timepoint: Baseline, 8 weeks, and 12 weeks.

Secondary

MeasureTime frame
Subjective assessment of hyperpigmentation improvement using the Melasma Area and Severity Index (MASI) questionnaire at baseline, 8 weeks, and 12 weeksTimepoint: Baseline, 8 weeks, and 12 weeks.

Countries

India

Contacts

Public ContactDr Vaidehi Raole

Parul Institute of Ayurved

vaidehi.raole@paruluniversity.ac.in9824284371

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026